Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181399 · ClinicalTrials.gov registry record · Phase 2
Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT03181399 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 45 participants.
The verdict
NCT03181399, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Forty-five subjects receiving no dietary therapy with a proven G1D diagnosis will be enrolled. To evaluate the effect of C7 supplementation of a regular diet on a EEG activity in addition to IQ, language, working memory, processing speed, emotional and behavioral functioning, ataxia, and other neuropsychological and neurological performance indices in children and adults genetically diagnosed with G1D receiving a regular diet at enrollment.
Interventions
- DRUG Triheptanoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2023-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03181399
The ClinicalTrials.gov registry entry for NCT03181399 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triheptanoin is the first listed.
NCT03181399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03181399 about?
NCT03181399 is a clinical study titled "Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)". Forty-five subjects receiving no dietary therapy with a proven G1D diagnosis will be enrolled. To evaluate the effect of C7 supplementation of a regular diet on a EEG activity in addition to IQ, language, working memory, processing speed, emotional and behavioral functioning, ataxia, and other neuro...
What is the current status of trial NCT03181399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2018-04-18. Estimated completion is 2023-09-10.
What interventions are being tested in trial NCT03181399?
The interventions under investigation include: Triheptanoin (DRUG).
Who is sponsoring clinical trial NCT03181399?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.